Sanofi Pasteur Limited has a long history of supporting science education at the post-secondary level. In 1994, we recognized the need to engage younger students in biotechnology education, and the initial SBC program was run in conjunction with the Biotechnology Industry Organization’s first meeting in Canada. Since then, the program has expanded from Toronto to 13 events across Canada and has involved thousands of students. As lead sponsor of the SBC, Sanofi Pasteur is proud to collaborate with partners in government, industry and academia to get high school students engaged in biotechnology.
Sanofi Pasteur Limited is Canada’s only full-scale vaccine company. We research, develop and manufacture a broad range of human vaccines right here in Canada. With over 1,000 highly-skilled employees, we are one of Canada’s oldest and largest biotech companies.
Sanofi, the parent company of Sanofi Pasteur, is a global and diversified health care leader that discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of health care with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer health care, emerging markets, animal health and the new Genzyme.
The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.
CDRD works in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.
In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. They are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.
DelMar Pharmaceuticals have also acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.
They are dedicated to benefiting patients and creating shareholder value by rapidly developing and commercializing anti-cancer therapies in cancer indications where patients have failed or are unlikely to respond to modern therapy.
The National Research Council (NRC), the Government of Canada’s premier organization for research and development, recognizes that young Canadians need to understand the benefits of learning science for their future careers in a complex, technological society. NRC pursues science promotion activities in communities across Canada and publishes resource materials to promote awareness of science, technology and engineering to youth.